<DOC>
	<DOCNO>NCT00306111</DOCNO>
	<brief_summary>The purpose study compare ability pegfilgrastim vs. filgrastim mobilize peripheral blood stem cell patient Non Hodgkin-lymphoma intraindividual study</brief_summary>
	<brief_title>Pegfilgrastim vs. Filgrastim - Comparison Mobilized Blood Stem Cells Patients With Non Hodgkin-lymphoma</brief_title>
	<detailed_description>Patients Non Hodgkin-lymphoma undergoing stem cell mobilization plan high-dose therapy treat two cycle chemotherapy ( etoposide , ifosfamide , cisplatin , epirubicin ) , either follow daily administration filgrastim ( first cycle ) pegfilgrastim ( second cycle ) . The number circulate cluster differentiation 34+ cell , colony-forming unit primitive progenitor analyze corresponding time point . Peripheral blood stem cell collect second cycle chemotherapy leukapheresis . After second cycle , high-dose therapy peripheral blood stem cell support administer ( protocol choose accord diagnosis , include total body irradiation-containing regimen ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>histological diagnosis nonHodgkin lymphoma plan highdose therapy autologous stem cell transplantation WHO performance status 02 write consent allergy ( peg ) filgrastim life expectancy &lt; 3 month malignant disease within last 5 year cardial insufficiency ( &gt; = New York Heart Association IIÂ° ) uncontrolled infection pregnancy , lactation central nervous system lymphoma Karnofsky score &lt; 70 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stem cell transplantation</keyword>
	<keyword>stem cell mobilization</keyword>
	<keyword>high-dose therapy</keyword>
</DOC>